Children who suffer a relapse of the aggressive cancer known as neuroblastoma have small chances of survival. However, a researcher group has now shown that DHODH blockers, which are well-tolerated in humans, can cure neuroblastoma in mice if administered in combination with chemotherapy. The study, published in the journal JCI Insight, paves the way for clinical trials of this combination therapy.
Neuroblastomas are tumors of nerve tissue that are typically diagnosed in very young children, normally before the age of two. The disease affects some 15 to 20 children in Sweden annually and is the deadliest form of cancer in infants. This new study shows that the protein DHODH (dihydroorotate dehydrogenase), which is involved in metabolism and DNA synthesis, also performs a key role in boosting the tumor growth of aggressive neuroblastomas.
“Through targeted treatment with specific DHODH blockers, we show in different cell and animal studies that cancer cells die, and that tumors stop growing,” says one of the study’s corresponding authors. “This is very promising, as DHODH blockers have been shown to be well-tolerated in clinical trials for other disorders.”
When the researchers combined DHODH blockers with a chemotherapy already in use for the treatment of children with neuroblastoma, they succeeded in curing mice with an aggressive variant of the disease.
“This combination therapy should be tested clinically as it has the potential to improve survival in children with neuroblastoma,” says the author. “This is sorely needed since the chances of survival on relapse are unfortunately small with current treatments.”
Analyzing patient data from over 600 children with neuroblastoma, the researchers found that tumors with high levels of DHODH are more aggressive and deadly. They then treated cell cultures and mice with a specific DHODH blocker called Brequinar.
When the researchers analyzed the gene expression in the tumors, they found that Brequinar reduces the activity of the MYCN gene, one of the “motors” that drives tumor growth. However, after treatment, the tumors began to grow again. This prompted the researchers to combine Brequinar with chemotherapy, which proved to be a recipe for success that cured the diseased mice.
https://insight.jci.org/articles/view/153836
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fdhodh-is-an-independent&filter=22
A prognostic marker and potent therapeutic target in neuroblastoma identified
- 908 views
- Added
Edited
Latest News
Serotonin 2C receptor regul…
By newseditor
Posted 02 Jul
First TB specific PET scan
By newseditor
Posted 02 Jul
Molecular mechanisms of som…
By newseditor
Posted 01 Jul
A distinct macrophage popul…
By newseditor
Posted 30 Jun
Sex differences in neurolog…
By newseditor
Posted 30 Jun
Other Top Stories
Statins reduce brown adipose tissue!
Read more
Autologous stem cell grafts for epilepsy treatment
Read more
Regrowing damaged nerves hinges on shutting down key genes
Read more
High blood sugar during pregnancy is associated with congenital hea…
Read more
Parkin delays cell death by targeting death protein!
Read more
Protocols
Monitoring norepinephrine r…
By newseditor
Posted 01 Jul
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Deciphering spatial domains…
By newseditor
Posted 23 Jun
High-throughput volumetric…
By newseditor
Posted 21 Jun
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Publications
Bidirectional brain-body in…
By newseditor
Posted 02 Jul
Neural circuits expressing…
By newseditor
Posted 02 Jul
Distributable, metabolic PE…
By newseditor
Posted 02 Jul
The use of experimentally e…
By newseditor
Posted 01 Jul
Monitoring melanoma patient…
By newseditor
Posted 30 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar